Prices steady, sales up in cold/allergy/sinus

February 2016
Drug Store News;Feb2016, Vol. 38 Issue 2, p14
Trade Publication
The article focuses on the annual dollar sales by several private-label products for cold, allergy, and sinus category tablets in 2015 including Zyrtec, Claritin, and Allegra. Topics mentioned include the revenue for drug sales, the price increase management, and the retail sales management. Also mentioned are the market share by the drug industry and the price of the Alka-Seltzer Plus cold medicine.


Related Articles

  • Ipsen's 1st Qtr 2012 Sales.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article reports on the sales report in the first quarter in the year 2012 of the pharmaceutical company Ipsen. The drug sales excluding foreign exchange impacts of the company increased in comparison to the previous years and the sales generated in the European countries decreased....

  • Generics take off in France.  // PharmacoEconomics & Outcomes News;7/1/2006, Issue 506, p10 

    This article reports that the market share of generics in France has exceeded its 2006 mid-year target in March. The reason behind the market share gains is discussed. A positive outlook was expressed by France's national health insurer, CNAM regarding the generic drug market. There is a...

  • 'Channel creep' erodes drug's share, shifts OTC sales to dollar stores. Johnsen, Michael // Drug Store News;4/19/2004, Vol. 26 Issue 6, p39 

    Comments on the effort of the pharmaceutical industry in developing their market strategy in the U.S. Determination of the pricing strategy; Proliferation of dollar stores in urban centers; Identification of market share for drug stores.

  • China Pharmaceutical & Medicine Market Report 2011.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p704 

    The article announces the addition of the report entitled "China Pharmaceutical & Medicine Market Report" to the offering of Research and Markets Ltd. (R&M). It provides information on the development of the country's pharmaceutical & medicine market. It analyzes the market's size and share, as...

  • BECTON DICKINSON & CO.  // MondayMorning;8/6/2012, Vol. 20 Issue 31, p1 

    The article provides information on the third-quarter income of Becton Dickinson & Co. that has fallen to 4.7 percent reducing the full year earning of the company in 2012. It states that the company expects to earn 5.33 dollar and 5.38 dollar per share in the year 2012, increasing the revenue...

  • PayPal Sinks On First Report. Investor's Business Daily // Investors Business Daily;10/29/2015, pA01 

    5 In its first quarterly report as a stand-alone company,

  • Glaxo hurt by Advair scandal. Investor's Business Daily // Investors Business Daily;5/1/2014, pA02 

    The U.K.'s biggest drugmaker said Q1 EPS fell 15% to 70 cents, topping analyst estimates. Sales fell 5% to $9.47 bil, missing.

  • Sun Pharmaceutical (Code: 524715) (CMP: Rs.842) (TGT: Rs.990). Gupta, Amit Kumar // Money Times;11/24/2014, Vol. 24 Issue 3, p13 

    The article offers stocks analysis of multinational pharmaceutical company Sun Pharmaceutical Industries Ltd. It states that stock price of the company is expected to be 1000 rupees. It mentions an increase in business revenue and net sales of the company. Sun's expectation regarding its...

  • Seeding Beyond the Base. Looney, William // Pharmaceutical Executive;May2012, Vol. 32 Issue 5, p12 

    In this article the author discusses the performance of the pharmaceutical industry during 2011. According to the author, revenues for the companies rated under the Pharm Exec 50 rose only just above the rate of inflation, at 2.8 percent. The author says that earnings before interest, taxes, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics